Biotech Values

[10nisman]

MNTA/TEVA

Just got an indirect (from an analyst who met Teva's CFO) reply....He knows about the "rumors". Teva normally do not discuss its API suppliers or product sources. About 40% of this generic product comes from out source. He knows ItalFarmaco and its drug marketed in India by Lupin. Teva's generic is different from Lupin's.

For a company the size of Teva, with the amount of drugs on-the market and in the pipeline, why would Teva's CFO have detailed knowledge of tL specifics other than partnership terms and specific financial performance related to the program? Teva's CFO would likely be one of the last executives I would ask to obtain specifics of tL.

Does anyone know how the FDA and Pharma prevent information leaks from their staff? I've spent a long time in the world of public accounting and although the firms have stricter independence rules regarding investment holdings than the SEC mandates, it is very common for staff working on M&A deals and other confidential projects to speak openly about the specifics. Their rationale is generally if we know about it so do a lot of other people (I-bankers, lawyers, certain employees, etc.).

So, I find it surprising in today's world of instant communication (text messages, tweets, facebook, etc.) that someone with intimate knowledge of tL hasn't accidentially or purposefully leaked information to someone they know - other than DD's unnamed person.

10nis